Elderly patients with myelodysplastic syndromes or acute myeloid leukemia can find long-term survival after undergoing stem cell transplantation transplantation, according to a recent study of the MD Anderson Cancer Center in Houston.
Although the number of patients long-term disease control, many patients still relapsed or died of transplant-related causes. The study investigators recognize that new methods of treatment are necessary to solve a number of attacks and deaths related to transplantation.
The results were presented in a poster session at the American Society of Clinical Oncology Article ASCO) 2012 meeting in Chicago earlier this month.
In patients with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) and source (Allogeneic) stem cell transplantation is currently the only curative treatment is available. Patients with MDS or AML produce stem cells that are not properly developed in the work cell. The donor stem cell transplantation transplantation, patients undergoing high-dose chemotherapy to destroy their own stem cells, which are later komi stem cells from healthy donors.
Donor stem cell collection transplantation has traditionally been used only in younger patients because of potential side effects and complications related to procedures, which can be particularly difficult in elderly patients.
In this study, researchers announced the results of the survival of 182 elderly patients with MDS or AML undergoing donor stem cell transplant graft at MD Anderson Cancer Center in Houston between 1996 and 2011. All patients in the study were older than 64 years, median patient age was 67 years. Of the 182 patients at diagnosis, 39 had MDS.
Median follow-up time for living patients was 12.6 months. The overall survival was 45 percent in one year after transplant, 28 percent in three years after transplantation, and 21 percent at five years after transplantation.
Three-year overall survival rate was higher in patients who received transplants at all forgiveness than for those with active disease 40 percent vs. 23 percent). Similarly, patients from age 65 to 69 with higher three-year overall survival rate than those aged 69 (30 percent versus 20 percent).
Within 100 days after transplantation, 14 percent of patients died of transplant-related causes. The combined incidence of death from transplant-related causes increased by 18 percent in one year and 21 percent in three years.
Within one year after transplant, 46 percent of patients relapsed. Within three and five years after transplantation, 53 percent of patients relapsed.
Twenty-six percent of patients in moderate to fatal acute graft-versus-host disease that develops within 100 days after transplantation. Graft-versus-host disease is a common complication of transplantation donor immune cells recognize the recipient's cells as foreign and attack them. An additional 35 percent experienced chronic graft-versus-host disease that develops after 100 days after transplantation.
Although the number of patients long-term disease control, many patients still relapsed or died of transplant-related causes. The study investigators recognize that new methods of treatment are necessary to solve a number of attacks and deaths related to transplantation.
The results were presented in a poster session at the American Society of Clinical Oncology Article ASCO) 2012 meeting in Chicago earlier this month.
In patients with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) and source (Allogeneic) stem cell transplantation is currently the only curative treatment is available. Patients with MDS or AML produce stem cells that are not properly developed in the work cell. The donor stem cell transplantation transplantation, patients undergoing high-dose chemotherapy to destroy their own stem cells, which are later komi stem cells from healthy donors.
Donor stem cell collection transplantation has traditionally been used only in younger patients because of potential side effects and complications related to procedures, which can be particularly difficult in elderly patients.
In this study, researchers announced the results of the survival of 182 elderly patients with MDS or AML undergoing donor stem cell transplant graft at MD Anderson Cancer Center in Houston between 1996 and 2011. All patients in the study were older than 64 years, median patient age was 67 years. Of the 182 patients at diagnosis, 39 had MDS.
Median follow-up time for living patients was 12.6 months. The overall survival was 45 percent in one year after transplant, 28 percent in three years after transplantation, and 21 percent at five years after transplantation.
Three-year overall survival rate was higher in patients who received transplants at all forgiveness than for those with active disease 40 percent vs. 23 percent). Similarly, patients from age 65 to 69 with higher three-year overall survival rate than those aged 69 (30 percent versus 20 percent).
Within 100 days after transplantation, 14 percent of patients died of transplant-related causes. The combined incidence of death from transplant-related causes increased by 18 percent in one year and 21 percent in three years.
Within one year after transplant, 46 percent of patients relapsed. Within three and five years after transplantation, 53 percent of patients relapsed.
Twenty-six percent of patients in moderate to fatal acute graft-versus-host disease that develops within 100 days after transplantation. Graft-versus-host disease is a common complication of transplantation donor immune cells recognize the recipient's cells as foreign and attack them. An additional 35 percent experienced chronic graft-versus-host disease that develops after 100 days after transplantation.
